The trial found a reduction in HFH, urgent HF visits, or cardiovascular death with dapagliflozin compared to placebo (16.4% versus 19.5%
8 People living with MASH are often asymptomatic or present with nonspecific symptoms in the early stages of the disease, which may result in a delayed diagnosis
Read more at: #Bioglutide To view or add a comment, sign in - Innovent Biologics has published results from the Phase 3 trial #DREAMS3 showing that their dual-receptor agonist #Mazdutide achieved significantly better outcomes than #Semaglutide in Chinese adults with type 2 diabetes (T2D) and #obesity
The right treatment approach depends on: your health history, body composition goals, side effect tolerance, metabolism, lifestyle, and long-term goals
While these are smaller single studies, taken together these articles identify possible new tools in an overall assessment, and highlight the benefits of using functional nutrition and lifestyle medicine
Proper preparation helps with both clinical accuracy and the ability to defend documentation during payer review
